U.S. markets closed

  • S&P Futures

    3,827.25
    +1.75 (+0.05%)
     

  • Dow Futures

    30,950.00
    +17.00 (+0.05%)
     

  • Nasdaq Futures

    11,681.50
    +7.25 (+0.06%)
     

  • Russell 2000 Futures

    1,739.00
    +0.70 (+0.04%)
     

  • Crude Oil

    111.03
    -0.73 (-0.65%)
     

  • Gold

    1,823.10
    +1.90 (+0.10%)
     

  • Silver

    20.78
    -0.03 (-0.12%)
     

  • EUR/USD

    1.0532
    +0.0007 (+0.06%)
     

  • 10-Yr Bond

    3.2060
    +0.0120 (+0.38%)
     

  • Vix

    28.36
    +1.41 (+5.23%)
     

  • GBP/USD

    1.2205
    +0.0020 (+0.17%)
     

  • USD/JPY

    136.0350
    -0.0930 (-0.07%)
     

  • BTC-USD

    20,331.93
    -267.72 (-1.30%)
     

  • CMC Crypto 200

    440.83
    -9.23 (-2.05%)
     

  • FTSE 100

    7,323.41
    +65.09 (+0.90%)
     

  • Nikkei 225

    26,756.04
    -293.43 (-1.08%)
     

Arvinas Highlights New ARV-110 Data In Prostate Cancer Patients

  • Oops!
    Something went wrong.
    Please try again later.
Vandana Singh
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • ARVN

Arvinas Inc (NASDAQ: ARVN) announced the presentation of new data from completed Phase 1 dose-escalation and ongoing Phase 2 ARDENT expansion cohort with bavdegalutamide (ARV-110).

  • The data were shared at the 2022 American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium.

  • The data showed that bavdegalutamide continues to provide evidence of anti-tumor activity and patient benefit in metastatic castration-resistant prostate cancer (mCRPC).

  • Bavdegalutamide reduced prostate-specific antigen (PSA) levels greater than or equal to 50% (PSA50) in 46% of patients with tumors harboring AR T878X/H875Y mutations.

  • Also See: Arvinas, Pfizer's ARV-471 Shows Clinical Benefit Rate Of 40% In Pretreated Breast Cancer Patients.

  • The Company plans to initiate a pivotal trial by year-end 2022.

  • Two confirmed partial responses were observed out of seven evaluable patients with AR T878X/H875Y tumor mutations.

  • PSA50 rate of 26% (five of 19) in evaluable patients in the subgroup defined as "less pretreated" (having received only one prior hormonal agent and no prior chemotherapy).

  • Most treatment-related adverse events (TRAEs) were mild to moderate, and there were no serious/life-threatening TRAEs in the 113 patients treated at the recommended 420 mg dose.

  • Price Action: ARVN shares were down 4.93% at $71.82 during the market session on the last check Tuesday.

See more from Benzinga

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Recommended Stories

  • ‘Simply Outrageous:’ EY Hit With $100 Million Fine After Audit Employees Cheat on CPA Ethics Exam

    (Bloomberg) -- Ernst & Young LLP admitted that dozens of its audit personnel cheated on the ethics portion of the Certified Public Accountant exam and that the firm misled US regulators probing the misconduct, according to the Securities and Exchange Commission.Most Read from BloombergRussia Slips Into Historic Default as Sanctions Muddy Next StepsBig Tech Sinks Stocks Bruised by Recession Jitters: Markets WrapMichael Burry of ‘The Big Short’ Fame Warns Fed May Alter CourseChina Cuts Travel Quar

  • ‘This recession will be the most severe yet’: Peter Schiff called the 2008 financial crash and now says the next downturn will be worse. Here's what he likes for safety

    Schiff publicly predicted the great financial crash of 2008. Will he be right again?

  • Dow Jones Dives As Inflation Fears Rise; This Stock Pops As Warren Buffett Raises Stake; Nike Plunges

    The Dow Jones fell as inflation fears rose. A Warren Buffett stock rose after Berkshire Hathaway raised its stake. Nike and Apple stock fell.

  • Cathie Wood: I Erred On Inflation, But Recession is Here

    Hotshot investor Cathie Wood, chief executive of Ark Investment Management, has said repeatedly in recent weeks that we're headed for disinflation soon. Consumer prices soared 8.6% in the 12 months through May, a 40-year high. "We were wrong on one thing and that was inflation being as sustained as it has been," Wood told CNBC.

  • Pay Fewer Taxes on Your Retirement Income With This Withdrawal Strategy

    Looking to pay fewer taxes on your hard-earned retirement income and extend the life of your savings? Doing so may be easier and simpler than you expected. For retirees with assets spread across various buckets, from taxable investment accounts to … Continue reading → The post Pay Fewer Taxes on Your Retirement Income With This Withdrawal Strategy appeared first on SmartAsset Blog.

  • Dow Jones Futures: Market Rally Flashes Very Bearish Signal; 5 Stocks To Watch

    Dow Jones futures rose slightly overnight, along with S&P 500 futures and Nasdaq futures. The stock market rally suffered sharp losses Tuesday, with the Nasdaq and S&P 500 breaking below a key level. Economic reports revived recession and inflation fears.

  • Why Carvana Stock Is Falling Hard Today

    Shares of the online car-buying company Carvana (NYSE: CVNA) were plunging this morning, likely after a Barron's article published over the weekend said that the company, in some cases, sold cars before it even had the title to them. Barron's said in its reporting that Carvana was selling cars too quickly during the pandemic, when demand for buying a car online soared, which led to problems in receiving the proper title for vehicles for some customers. Apparently, enough people have experienced this problem that a lawsuit is being brought against the car seller, saying that some customers went years without legally being able to drive vehicles purchased from Carvana.

  • Pfizer, Moderna, Novavax: FDA Experts Vote 19-2 To Include Omicron Shot In Covid Boosters

    A split FDA panel voted Tuesday to recommend including an omicron component in updated Covid boosters this fall.

  • Hedge Funds Brace for Impact: Top 10 Stocks to Dump Now

    In this article, we discuss the top 10 stocks to dump now according to hedge funds as they brace for impact. If you want to see more stocks in this list, click Hedge Funds Brace for Impact: Top 5 Stocks to Dump Now. Elite hedge funds in the United States are exceedingly cautious with their […]

  • Shopify Stock Split: What the Charts Say Ahead of 10-for-1 Split

    Not a lot of positives surround Shopify at the moment. Unfortunately for many investors, that disappointment is not limited to just Shopify, but also includes most growth stocks at the moment. Many growth stocks are down 60% to 70% or more.

  • 2 “Strong Buy” Dividend Stocks With at Least 7% Dividend Yield

    We’re facing a maelstrom of conflicting currents in the markets today, with a series of headwinds running head-on into each other. Consumer sentiment is low – in fact, at the lowest levels ever recorded, with 79% of consumers expecting economic conditions to get worse in the coming year. Inflation is high, at levels not seen since 1981, and is expected to remain elevated through the end of 2023. Fuel prices are major driver with the national average for a gallon of gasoline exceeding $5. The hou

  • Qualcomm Spikes on Report It Will Remain iPhone 5G Modem Chip Supplier in 2023

    Taiwan-based hardware analyst Ming-Chi Kuo says Qualcomm will hold on to 100% of the Apple modem supply for the 2023 iPhones. Qualcomm shares soared Tuesday on a report that Apple’s push to develop modem chips for the iPhone “may have failed,” and that Qualcomm will remain the exclusive supplier of 5G chips for phones to be launched in the 2023 second half. Writing on Twitter, the Taiwan-based hardware analyst Ming-Chi Kuo said that Qualcomm (ticker: QCOM) will hold on to 100% of the Apple (AAPL) modem supply for the 2023 iPhones vs the company’s own previous estimate of 20%.

  • Mr. Big Short: Fed May do a 180 on Interest Rates

    The Federal Reserve has raised the fed funds rate target by 150 basis points since March, and many experts expect a lot more.

  • The bottom of the bear market is still 10% away, Morgan Stanley Wealth Management says. And the odds of a recession have doubled, too

    Lisa Shalett, Morgan Stanley Wealth Management’s chief investment officer, says the odds of a recession are now over 50%.

  • New to Dividend Stocks? Start by Buying These 3 Ultra-Safe Picks

    Investors might be skeptical to put their money in the stock market now given the current market scenario. Excellent growth stocks are trading at a bargain now. Investors new to dividend stocks can consider these three that belong to an exclusive group of Dividend Kings.

  • Why the S&P 500 may be in for a 1966-style bear market, according to DWS Group

    David Bianco, chief investment officer Americas at DWS Group, has a price target for the S&P 500 of 3,700 to f 4,100 for the second half of the year.

  • Mystery rocket leaves double crater on the moon

    There is a double mystery on the moon involving a rocket that crashed there. First there's no idea who launched the rocket but the bigger mystery is why did it leave two craters? NASA says astronomers noticed the rocket on a collision course with the moon last year.

  • Doomed Stock Rally Burns Fewer Bulls After $10 Billion ETF Exit —

    (Bloomberg) -- Stock dip-buyers across the ETF world have vanished after seeing their account balances ravaged too many times in the 2022 meltdown.Most Read from BloombergRussia Slips Into Historic Default as Sanctions Muddy Next StepsBig Tech Sinks Stocks Bruised by Recession Jitters: Markets WrapChina Cuts Travel Quarantine in Biggest Covid Zero Shift YetMichael Burry of ‘The Big Short’ Fame Warns Fed May Alter CourseA $2 Trillion Free-Fall Rattles Crypto to the CoreThree times, to be specific

  • Markets: ‘You’re getting closer to a bottom,’ strategist says

    Northwestern Mutual Wealth Management Company CIO Brent Schutte joins Yahoo Finance Live to track the performances of tech and energy stocks alongside market movements, volatility amid inflation and the Fed's interest rate hike, and comparisons to past economic environments.

  • Why Congress’ new retirement reforms aren’t all they’re cracked up to be

    A new set of reforms to America’s retirement tax and savings plans passed a key hurdle in Congress last week. Variously known as the SECURE Act 2.0, the EARN Act and the RISE & SHINE Act, the measures will make changes to rules around IRAs, 401(k)s and other tax-privileged retirement plans. They barely address the biggest retirement crisis facing the U.S.